CD19-directed Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL). The gene discussed is CD19; the disease is precursor B-cell acute lymphoblastic leukemia.